| Assessment Status | Rapid Review complete |
| HTA ID | 21003 |
| Drug | Ceftazidime/avibactam |
| Brand | Zavicefta® |
| Indication | For paediatric patients aged three months and older for the treatment of: Complicated intra-abdominal infection (cIAI); Complicated urinary tract infection (cUTI), including pyelonephritis; Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP); Infections due to aerobic Gram-negative organisms in patients with limited treatment options |
| Assessment Process | |
| Rapid review commissioned | 09/02/2021 |
| Rapid review completed | 04/03/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that of ceftazidime-Avibactam (Zavicefta®) not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
